Showing results (51-60 of 702) with videos related to
Sort By:
Pageof 71
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trialLars Rolighed, Lars Rejnmark, Tanja Sikjaer, et al.Current Drug Safety|April 29, 2011
Emerging anabolic treatments in osteoporosisLeif Mosekilde, Ove Tørring, Lars RejnmarkCurrent Drug Safety|April 29, 2011
PTH treatment in hypoparathyroidismTanja Sikjaer, Lars Rejnmark, Leif MosekildeOsteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 19, 2004
Hip fracture risk in statin users--a population-based Danish case-control studyLars Rejnmark, Mette Lena Olsen, Søren Paaske Johnsen, et al.Calcified Tissue International|December 14, 2004
Fracture risk in perimenopausal women treated with beta-blockersLars Rejnmark, Peter Vestergaard, Moustapha Kassem, et al.The American Journal of Clinical Nutrition|June 21, 2013
Cobalamin and haptocorrin in human milk and cobalamin-related variables in mother and child: a 9-mo longitudinal studyEva Greibe, Dorte L Lildballe, Súsanna Streym, et al.Clinical Endocrinology|November 4, 2010
Vitamin D status, physical performance and body mass in patients surgically cured for primary hyperparathyroidism compared with healthy controls - a cross-sectional studyAnne Kristine Amstrup, Lars Rejnmark, Peter Vestergaard, et al.Ugeskrift for Laeger|September 8, 2009
[Medical treatment of patients with primary hyperparathyroidism]Peter Vestergaard, Leif MosekildeThyroid : Official Journal of the American Thyroid Association|August 22, 2003
Hyperthyroidism, bone mineral, and fracture risk--a meta-analysisPeter Vestergaard, Leif MosekildeBMJ (Clinical Research Ed.)|September 6, 2003
Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidismPeter Vestergaard, Leif MosekildePageof 71